Answers are grounded in this paper and cite their sources.
Evaluation of controlled release lornoxicam in biphasic-release tablets suggests improved dosing flexibility.
The developed biphasic-release MUTs provide rapid onset, sustained LOX delivery, and reliable dose flexibility, representing a promising oral formulation for LOX therapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: